We endeavor to review important new advances in acute pancreatitis made in the past year. We focused on clinical aspects of acute pancreatitis, which contained new observations or insights into new or old concepts. For experimental acute pancreatitis we refer readers to a recent comprehensive review.
Introduction
In this review of acute pancreatitis we focus on epidemiology, etiology, demographics and risk stratification. We also discuss advances in treatment, including chemoprevention of post-endoscopic retrograde cholangiopancreatography (ERCP) acute pancreatitis, and enteral and antibiotic therapy. For experimental acute pancreatitis we truncate our comments and refer readers to a recent comprehensive review.
Epidemiology
Two studies describe long-term trends in acute pancreatitis [1 ,2 ] . Yadav and Lowenfels [1 ] reviewed the results of 12 longitudinal studies to determine long-term trends in the epidemiology of the first attack of acute pancreatitis in the UK, non-UK European countries and Iceland. The predominant age of the onset of acute pancreatitis was the sixth decade. The most common causes were gallstones (10.8-56%), idiopathic (8-44%) and alcohol (3-66%). Idiopathic acute pancreatitis (IAP) was the most common cause in the UK and alcoholic acute pancreatitis was most common in other countries. An increasing incidence of acute pancreatitis was noted in 10 studies [1 ], mostly due to alcoholic pancreatitis in non-UK countries (Sweden, Denmark, Netherlands); gallstone pancreatitis increased in all countries, but less so. Routine serum pancreatic enzyme testing in emergency departments may partially account for the increasing diagnoses of acute pancreatitis, particularly milder cases of acute pancreatitis, or mistakenly diagnosing acute pancreatitis for other conditions that cause hyperenzymemia. The proportion of patients with recurrent acute pancreatitis (RAP) decreased from 18-31% to 4.2-14.4%, an observation possibly explained by improved diagnosis of chronic pancreatitis, which commonly presents with recurrent attacks of pain. Population-based mortality rates were stable. Case fatality rates decreased from 15-20% to under 5% [1 ] . Mortality increased with age (<5% for age <40 years; 30-40% for age >80 years). Sixty-five per cent of deaths occurred within 14 days and 80% within 30 days. Many studies reported similar mortality rates among causes of acute pancreatitis.
In California, Frey et al.
[2 ] reported a 32% increase in the age-standardized incidence of acute pancreatitis based on a multiethnic cohort of patients hospitalized between 1994 and 2001. Biliary pancreatitis (52%) increased more than alcohol (12%) or idiopathic (18%) groups. The most common causes of first-attack acute pancreatitis were idiopathic (36.6%), biliary (32.6%) and alcohol (20.3%). The 14-or 91-day case fatality rate did not decrease, likely because case fatality rates were already under 6%, similar to recent data from the UK which reported an initial decline and then a plateau in case fatality rates at 6-7%. Further decline of the case fatality rate will likely require innovations of patient management. Older age was the greatest 14 and 91-day fatality risk factor. Alcoholic acute pancreatitis had the greatest mortality rate standardized for age, race and sex, consistent with data that as many as one third of deaths related to acute pancreatitis never make it to the hospital and up to 75% of these are alcoholic in cause. For unclear reasons, standardized case fatality rates remained elevated even 9-12 months after hospitalization. The authors uncovered a major management error: only 43% of patients with biliary acute pancreatitis had same hospitalization cholecystectomy, thus exposing unoperated patients to the risk of a second episode.
Specific causes
Recent publications report data on acute pancreatitis related to alcohol, gallstones, rare diseases, iatrogenic causes and medications.
Alcohol
A simple test to predict alcohol as the cause of an attack of pancreatitis would be useful because it is often difficult to obtain a reliable alcohol history. Such a test may be carbohydrate deficient transferrin (CDT). In an editorial Perez-Mateo [3 ] pointed out that a CDT level greater than 17 U/l is 27% sensitive and 100% specific for predicting alcoholic acute pancreatitis, and by multivariate analysis elevated levels of CDT and serum trypsin correctly identified 98% of patients.
Gallstones
Hospitalization for gallstone-associated disease related to pregnancy (during pregnancy and within 1 year postpartum) is more common than usually recognized, perhaps occurring in approximately 0.5% of all births, and many of these patients may incur acute pancreatitis [4 ] . In this retrospective case controlled study of 6670 patients with gallstone related hospitalization, most (76%) had uncomplicated cholelithiasis, but 16% had acute pancreatitis. Gallstone related hospitalizations were greater for Native Americans and for women who were younger, overweight or obese.
Rare diseases
Rare diseases associated with acute pancreatitis include mitochondrial cytopathy, a group of diseases characterized by deletion or depletion of mitochondrial DNA. Debray et al.
[5] reported a patient with acute pancreatitis who had Karnes Sayre syndrome, a mitochondrial disease characterized by the triad of external ophthalmoplegia, pigment retinopathy and heart block, cerebellar ataxia or cerebral spinal protein over 100 mg/ml, and documented this association in six other patients.
Iatrogenic
Although post-ERCP acute pancreatitis occurs in approximately 10% and may be severe [6], Bhatia et al.
[7 ] reported that it occurred in only 3.8% of 1497 ERCPs and 95% had mild disease. Similarly, acute pancreatitis after endoscopic ultrasonography (EUS)-guided fine needle aspiration of pancreatic masses is very low (three of 355 patients; 0.83%) and mild [8 ] .
Medications
The association of many medications with acute pancreatitis remains controversial. Some claim that any statin may cause a generally mild form of acute pancreatitis, but at a very low risk (odds ratio 1.4) that is not dose related, and appears after months to years of therapy without relation to age [9] . Others, however, deny a strong association and suggest that statins may lessen the risk of acute pancreatitis by reducing hypertriglyceridemia [10] . There are many case reports of cyclo-oxygenase-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs causing acute pancreatitis. In a population-based case-control study of 3083 acute pancreatitis cases and 30 830 controls, Danish investigators established that all NSAIDs were associated with acute pancreatitis, but at a low relative risk of 1-3 [11] . The antihypertensives, angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers, have a moderately increased risk for acute pancreatitis (adjusted odds ratio 1.5 for each) [12 ], but loop, thiazide and potassium sparing diuretics do not. Higher doses of ACE inhibitor moderately increase the risk of acute pancreatitis, which is more frequent in the first 6 months of treatment, while calcium channel blockers have no dose or time relationship to acute pancreatitis [12 ] . Proton pump inhibitors and H2 blockers may increase the risk of acute pancreatitis, but these data are confounded because untreated gastroesophageal reflux disease and gastritis may increase the risk of acute pancreatitis [13] . Interestingly, valproic acid may not be an independent risk factor for acute pancreatitis because the adjusted odds ratio for acute pancreatitisin current users of valproic acid is 2.6, similar to the odds ratio of other antiepileptics [14] .
Idiopathic pancreatitis
Idiopathic pancreatitis commonly is classified as idiopathic acute pancreatitis (IAP), idiopathic recurrent acute pancreatitis (IRAP) and idiopathic chronic pancreatitis (ICP). IRAP, however, is uncommon, certainly less than 14% of persons with a first attack of acute pancreatitis [1 ], and should be restricted to patients who truly have an unknown cause of RAP. All other patients should be classed as RAP as most patients with the initial label of IRAP will eventually be found to have one of the causes of RAP including biliary disease (gallbladder microlithiasis, choledocholithiasis, biliary sludge), ICP, genetic abnormalities such as cystic fibrosis transmembrane conductance regulator (CFTR) or hereditary pancreatitis mutations, or unusual lesions such as ampullary lesions or pancreatic cancer. Whether pancreas divisum or sphincter of Oddi dysfunction (SOD) [6] cause RAP is controversial (see below). Few studies combine complete diagnostic testing with prospective follow-up, but patients most commonly have occult cholelithiasis or have or develop signs of ICP.
Data from a recently published long-term follow-up study by Garg et al. [15 ] indicate that ICP is a more common cause of RAP than biliary lithiasis [15 ] . They identified 75 patients with RAP and followed them prospectively for a mean of 18 months. Approximately 50% developed conclusive evidence of ICP by imaging studies (computed tomography, ERCP, ultrasound or EUS), and 16% had biliary lithiasis [microlithiasis (n ¼ 10) or gallstones (n ¼ 2)]. In this study two patients with overt gallstones had cholecystectomy and resolution of RAP, but eight of 10 patients with microlithiasis treated with cholecystectomy (n ¼ 4) or biliary sphincterotomy (n ¼ 4) had persistent RAP and developed ICP. Detection of ICP in the microlithiasis group suggests that microlithiasis was mis-diagnosed or lithogenic bile associates with ICP as it does with cystic fibrosis, a known cause of RAP. The response to cholecystectomy in patients with overt gallstone acute pancreatitis is similar to findings in a cohort of 2583 patients with gallstones, in which patients who had gallstone acute pancreatitis (3.4% of cohort) and a cholecystectomy had a risk of recurrent pancreatitis or chronic pancreatitis identical to the general population [16] . Overall, these data strengthen existing data that early ICP is a common cause of RAP, reported in 27% [17] and 39% (postcholecystectomy) [18] of patients followed prospectively for less than 3 years and up to 53% of patients with RAP associated with pancreas divisum [19 ] .
It is likely that early and late-onset ICP develop as a consequence of RAP due to unrecognized causes (genetic abnormalities or environmental factors) causing the necrosis-fibrosis sequence and what we now term ICP. Thus, at our current stage of knowledge, IRAP is an early manifestation of ICP. Support for this position resides in finding that ICP is characterized by recurrent attacks of pain for variable duration and frequency [20] [21] [22] , and that a proportion of patients (n ¼ 35) prospectively followed with RAP treated with or without pancreatic duct stenting develop ICP [17] . During a mean approximately 3-year follow-up, stenting reduced the frequency of attacks of 'acute pancreatitis' (53% versus 11%) but had no effect on pancreatic type pain (32% versus 40%) or the development of findings of ICP (27% versus 26%). Patients were excluded for overt chronic pancreatitis, gallstone disease, microlithiasis, alcohol, and SOD (by manometric criteria). This indicates that patients with RAP commonly have early ICP and pancreatic duct stenting does not prevent the course of ICP. We also speculate that in patients labeled as IRAP, manometric findings of SOD reported in 15-35% of patients [6] are less likely the cause of RAP and more likely the sequelae (inflammatory, fibrotic or neural) of ICP. A prospective follow-up study of patients with RAP and manometric findings of SOD to determine how many develop ICP could test this hypothesis.
Genetic analyses (and family history) may help predict ICP in patients with RAP. The frequency of CFTR gene mutations in patients previously thought to have idiopathic pancreatitis is 10-50%, depending upon the number of the approximately 1500 CFTR mutations tested. Notably, CFTR gene mutations are not associated with single episodes of acute pancreatitis [23] . Previously, Choudari et al. [24] reported a 19% frequency of CFTR mutations (based on a 13 CFTR panel) in patients originally classed as IRAP, a similar frequency to that reported in ICP (using a similar screening panel) [25, 26] . A higher prevalence of CFTR gene mutations was detected in idiopathic pancreatitis using exhaustive gene identification methods: 38% of those having IRAP and 45% of ICP [27] . Hence, the association of CFTR gene mutations with groups labeled as having IRAP [24, 27] has been interpreted by experts as further evidence that these patients have early-onset ICP with recurrent attacks of pain [28] .
Variations in patient selection and the pattern of referral may influence the yield of screening for CFTR mutations in idiopathic pancreatitis. For example, the Indiana group [29] reported a lower 8.4% frequency of CFTR mutations in patients with idiopathic pancreatitis compared to their earlier study [24] , even though they used a more extensive CFTR gene mutation panel (70 to 87 alleles) than in the earlier study [24] . The control and ICP patients had a high but similar frequency of pancreas divisum (30% and 20%, respectively), providing further support that pancreas divisum is not a cause of pancreatitis, a position we argue [19 ] , leading Fogel, Toth and Lehman, previously strong proponents of the association, to suggest, 'other predisposing factors such as CFTR mutations may be necessary for pancreatitis to occur in patients with pancreas divisum.' Finally, Alazmi et al. [29] reported that patients with CFTR mutations had more severe Cambridge criteria for chronic pancreatitis than the ICP control group, but the prognostic importance of this finding is unclear.
Management of presumed IAP is based upon the supposition that approximately 75% patients with IRAP have occult cholelithiasis (based upon gallbladder imaging or finding microlithiasis in bile drainage) and treatment significantly reduces risk of RAP. Evans and Draganov [30] argue that in the absence of randomized controlled trials (RCTs) that compare laparoscopic cholecystectomy, biliary sphincterotomy and ursodeoxycholic acid, laparoscopic cholecystectomy is preferred because of safety and almost certain cessation of future attacks. An interpretation of the study by Garg et al. [8 ] , however, suggests that cholecystectomy or biliary sphincterotomy should not be done in patients with RAP unless microlithiasis (or perhaps sludge) is suspected by finding elevated liver tests or confirmed by ultrasound or bile crystal analysis. A small proportion of RAP patients, however, may have biliary lithiasis undetected by testing and deserving of a laparoscopic cholecystectomy.
Demographics and risk stratification
Recent studies further clarify the predictors for severe acute pancreatitis, infected necrosis and mortality and the association between pancreatic necrosis and severity.
Demographic factors
Obese persons with acute pancreatitis have a greater probability of developing complications and severe disease, and they die more frequently [31 ] than nonobese persons, but it appears that among other factors obesity is not a risk factor for pancreatic necrosis (logistic regression) [32 ] . Alcohol intake of more than 2 drinks per day, however, may significantly increase the risk of developing pancreatic necrosis [32 ] regardless of the cause of the acute pancreatitis.
Prediction of severity
A search continues for a simple scoring system to accurately predict severity. Spitzer et al. [33] developed and retrospectively evaluated a four-component system (age !65 years, blood urea nitrogen !25 mg/dl, lactate dehydrogenase !300 IU/ml and IL-6 !300 pg/ml) and reported that it was as accurate as Ranson, Glasgow, and APACHE II scoring systems. Three and four positive factors incurred 25 and 50% mortality, respectively. Advantages of this system are simplicity and the ability to use it anytime during the first 48 h, but it has not been evaluated prospectively. Computer-assisted systems using machine learning methods (computer algorithms that improve automatically by experience) [34 ] including artificial neural networks [35 ] , may improve prediction of severity. Pearce et al. [34 ] demonstrated in a retrospective analysis of 265 patients with acute pancreatitis that a model based upon kernel logistic regression and bootstrapping employing eight variables [age, respiratory rate, C reactive protein (CRP), white blood cell count, arterial P O 2 on air, serum creatinine, arterial pH and Glasgow Coma Scale] was superior to APACHE II for predicting severity on admission with a sensitivity and specificity of 87 and 71%, respectively. Similarly, Mofidi et al. [35 ] showed that retrospectively an artificial neural network more accurately assessed severity and mortality than APACHE II and Glasgow scoring systems. At present these computer-learning methods appear promising but need to be trained and tested rigorously and prospectively.
Opinions differ about the relations among early systemic inflammatory response (SIRS), multisystem organ failure (multiple organ dysfunction syndrome; MODS), infection, severity and death in acute pancreatitis. As reviewed by Banks [36 ] , organ failure is more common in necrotizing than in interstitial acute pancreatitis (54% versus 10%) and mortality is higher in necrotizing than in interstitial acute pancreatitis (17% versus 3%) and in necrosis with MODS (47%) than in single organ failure (3%) and in no organ failure (0%). Further, organ failure is largely responsible for early deaths (within 1-2 weeks), which occur at least as frequently [36 ] and possibly more frequently [1 ] than later deaths, caused by infected necrosis or a complication of sterile necrosis. Mofidi et al. [37 ] emphasized the association between SIRS and MODS in 759 patients with acute pancreatitis and showed that persistent SIRS was associated with MODS and death. Rau et al. [38 ] compared the outcome of 135 patients with sterile pancreatic necrosis who underwent necrosectomy and 95 patients managed conservatively without operation and found that the major factors for developing pancreatic infection after operation were extent of necrosis and early MODS, but that death was related to MODS rather than necrosis or infection. These data contrast with earlier findings by Gö tzinger et al. [39] that by multivariate analysis the two factors that independently predict organ failure are extent of necrosis (in both sterile and infected necrosis) and infected necrosis, and that infected necrosis and APACHE II score predict mortality. The different conclusions in the Rau [38 ] versus Gö tzinger [39] studies are partially explained by the larger size and power of the Gö tzinger study, which had more patients with over 50% necrosis (138 versus 52) and under 50% necrosis (202 versus 165). The overall clinical implications are that persistent organ failure and extent of necrosis may be useful for predicting infected necrosis, but organ failure (particularly persistent organ failure and MODS) more New advances in acute pancreatitis DiMagno and DiMagno 497 reliably but not necessarily exclusively predicts increased mortality in acute pancreatitis.
Chemoprevention of post-endoscopic retrograde cholangiopancreatography pancreatitis
In the past year several groups have re-investigated chemoprevention (N-acetylcysteine [40] , octreotide [41, 42] , the protease inhibitors gabexate [43, 44] and ulinastatin [44] , and glyceryl trinitrate [45] ) of post-ERCP pancreatitis either by RCTs or meta-analyses [46 ,47] . Milewski et al. [40] confirmed that N-acetylcysteine was ineffective. Two groups conducted a RCT and claimed that octreotide prevented post-ERCP pancreatitis [41, 42] , but two groups previously showed that octreotide was ineffective [48, 49] , corroborating negative findings of a meta-analysis of 10 other clinical trials [50] . The variable results of the octreotide studies are likely due to marked differences among the studies such as drug dose and duration, population and endpoints; therefore, it is doubtful that an updated meta-analysis will draw a different conclusion. Results of meta-analyses indicate that the protease inhibitor ulinastatin is no more effective than gabexate at reducing post-ERCP acute pancreatitis [44] and that short or long-term infusion of gabexate does not reduce post-ERCP acute pancreatitis [46 ,47] . Similar to the octreotide studies, differences in study design and populations are present in studies designed to investigate if glyceryl dinitrate reduces post-ERCP pancreatitis; it was ineffective in a recent study [45] and beneficial in two prior studies [51, 52] . In summary, the results of the RCTs of chemoprevention therapy for post-ERCP pancreatitis are inconclusive and raise more questions than answers.
Enteral and parenteral feeding
Clinicians administer enteral feeding and parenteral feeding to patients with severe acute pancreatitis or who will not be able to consume food for several weeks. Enteral feeding is safer and costs less than parenteral feeding. The extent to which enteral feeding beneficially impacts acute pancreatitis is unclear. In a systematic review McClave et al.
[53 ] concluded, 'patients with severe acute pancreatitis should begin enteral feeding early because such therapy modulates the stress response, promotes rapid resolution of the disease process, and results in better outcome.' These recommendations mirror new guidelines from the European Society for Clinical Nutrition and Metabolism [54] and the American College of Gastroenterology (ACG) [36 ] . Three new studies advance understanding in this area.
Petrov et al. [55 ] report data on the largest cohort of patients (n ¼ 70) with predicted severe acute pancreatitis (based on APACHE II score >8 or CRP >150 mg/dl) who were randomized to enteral feeding versus parenteral feeding, started within 72 h from symptom onset. Both groups had similar rates of transient organ failure but the enteral feeding group had reduced persistent organ failure after 7 days (3% versus 23%), pancreatic infectious complications (20% versus 46%), MODS (20% versus 49%) and mortality (6% versus 34%), the latter occurring after 2 weeks in 57%. These striking findings seem too good to be true, possibly due to an unidentified bias, but if reproducible, would have a greater impact on mortality in severe acute pancreatitis than any known intervention.
In studies of patients with predicted severe acute pancreatitis, nasogastric enteral feeding is safe and well tolerated compared to jejunal enteral feeding [56] or to parenteral feeding [57] . The study of Kumar et al. [56] is difficult to interpret because patients started jejunal enteral feeding or parenteral feeding after markedly different durations of symptoms (1-32 days) as in the Eckerwall et al. study [57] , because only 46% of patients had severe acute pancreatitis by Atlanta criteria. Further the nasogastric enteral feeding group had more patients with pancreatic necrosis than the parenteral feeding group (30% versus 15%), which likely explains the higher complication rate and transiently greater intestinal permeability in the nasogastric enteral feeding group. Additional studies are required to determine the differential impact among nasogastric enteral feeding, nasojejunal enteral feeding and parenteral feeding in patients with severe acute pancreatitis, and to determine the appropriate time to start treatment, composition and volumes of enteral feeding.
Antibiotics
Does giving systemic antibiotics prophylactically to patients with severe necrotizing acute pancreatitis prevent pancreatic infection? As indicated by expert opinon [58] , ACG practice guidelines [36 ] and a meta-analysis [59] , large, well designed studies are lacking. Only one RCT was doubly blinded. Similar to the ACG guideline [36 ] the authors of the meta-analysis [59] conclude that prophylactic antibiotics reduce hospital stay but they do not reduce infected necrosis, mortality, nonpancreatic infections and the rate of surgical intervention. Lankisch and Lerch [58] provide four helpful criteria to justify administration of antibiotics: sepsis or SIRS, failure of one or more organs, proven pancreatic or extrapancreatic infection or an increase in CRP with evidence of pancreatic or extrapancreatic infection. Subsequent to these analyses Manes et al. [60] published a RCT indicating that the timing of administering antibiotics is important. Regardless of predicted severity of acute pancreatitis, patients were randomized to start meropenam immediately after hospitalization (day 1.1) or after diagnosis of pancreatic necrosis (day 4.5). Analysis was restricted to only those with verified pancreatic necrosis. Both groups had similar CRP values (215 versus 203 mg/dl) and numbers of patients divided according to percentage necrosis: under 30% (15 versus 14), 30-50% (eight versus seven), and over 50% (seven versus eight). Early antibiotic treatment reduced extra-pancreatic infection (17 versus 49%), need for surgery (13 versus 38%) and length of hospitalization (18 versus 30 days) but had no significant effect on pancreatic infections (13 versus 30%), single organ failure, MODS or mortality. Additional study is required to determine if the timing of starting antibiotics is critical, whether all patients should be treated initially with antibiotics until they are risk stratified, and whether the benefit outweighs the risk of developing antibiotic resistance.
Experimental pancreatitis
Multiple investigators have identified the major events leading to acinar cell injury and events subsequent to cell injury that determine the severity of acute pancreatitis (Table 1 ). These events have been described in clinically relevant experimental models, including the cystic fibrosis mouse model [61] and alcohol acute pancreatitis [62 ] . Important extrapancreatic factors that modulate pancreatitis include neural signaling and the vascular response; the latter has been a research focus of our group. For discussion of recent and past observation in experimental pancreatitis, we refer the reader to the recent, comprehensive review of this topic [62 ] .
Conclusion
We have endeavored to review clinical and basic research studies this past year that further characterize the epidemiology, etiology, and determinants of severity in acute pancreatitis. Importantly it is becoming evident that by thoroughly investigating and prospectively following patients previously labeled as IRAP, most will be found to have chronic pancreatitis or microlithiasis as a cause of RAP. Although therapies to lessen the severity and mortality of acute pancreatitis are lacking, potential therapeutic targets identified in experimental acute pancreatitis studies may translate to future, novel therapies offered at the bedside. New advances in acute pancreatitis DiMagno and DiMagno 499 
